The stock market has always known that excellence in Business Management distinguishes the best corporations. Marketing, Finance, and Human Resources Development are the key functional areas which the best-run corporations use to thrive in challenging business environments. Here is a … Continue reading →

Sirtris Pharmaceuticals (SIRT), based in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 diabetes. The … Continue reading →

AtheroGenics Inc. (NASDAQ: AGIX) today announced its “topline” results from an interim analysis of its ANDES Phase 3 clinical trial of AGI-1067, for the treatment of Type 2 diabetes, administered once daily for the duration of six months. According to … Continue reading →

AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, released news earlier this morning on a planned interim analysis of its ongoing ANDES Phase 3 clinical trial of AGI-1067 for the treatment of Type … Continue reading →

Technically, this stock is part of the Mobile Homes & RVs Industry in the Capital Goods Sector. Such a narrow stock market business definition is misleading for investors in this case. The stock shows its inherent value when we consider … Continue reading →

This stock has traded at the end of the second week of April 2008 at just $5.70. The Price to Earnings Ratio is below 11. Though institutions have firm grips on 95% of the stock, it is worth entering to … Continue reading →

Transition Therapeutics Inc. (TTHI), based in Toronto, Ontario, Canada, is a biopharmaceutical company that develops novel therapeutics for diseases which affect large portions of the population. The focus of the company is discovering and advancing lead molecules to the most … Continue reading →

Cell Genesys Inc. (CEGE) said Friday its GVAX immunotherapy treatment for recurrent prostate cancer did well in early stage clinical tests. Shares of the San Francisco, Calif.-based company were up nearly 4% to a high of $3.25 during late-day trading. … Continue reading →

The European Commission (EC) today announced that Celgene’s amrubicin hydrochloride has been designated as an orphan medicinal product for the treatment of small cell lung cancer. This follows the European Medicines Agency’s (EMEA) favorable opinion, issued by the EMEA’s Committee … Continue reading →

Altair Nanotechnologies, Inc., an innovator and supplier of advanced, novel, ceramic nanomaterials, announced it expanded its board to seven members by naming Robert G. van Schoonenberg as director. Mr. Schoonenberg also serves as Chair of the Audit Committee and as … Continue reading →